

MAUNA KEA TECHNOLOGIES RENEWS ITS EQUITY FINANCING FACILITY TO SUPPORT ITS DEVELOPMENT

Paris and Boston, October 6, 2017 – 5.45 PM CEST – Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio[®], the multidisciplinary confocal laser endomicroscopy platform, today announces the implementation of an equity financing facility with Kepler Cheuvreux. This will allow the Company to complete small successive capital increases at its own pace and timing. Mauna Kea secured its prior equity financing facility, also with Kepler Cheuvreux, in November 2016.

The CEO of the Company, acting with a delegation from the Board and in accordance with the 21st resolution approved by the General Meeting of Shareholders on May 3, 2017, decided today to implement this equity financing facility.

Pursuant to the terms of the agreement, Kepler Cheuvreux, acting as financial intermediary and underwriter for the transaction, gave a full and firm commitment to subscribe for 2,100,000 shares at its own initiative over a timeframe not exceeding 24 months. The shares will be issued based on the volume-weighted average price of the trading days preceding each issuance, minus a maximum discount of 6.5%.

Assuming the equity line facility were to be used in full⁽¹⁾, it would enable to raise €5.7 million in financing based on the current share price⁽²⁾. Subject to the contractual conditions being fulfilled, a shareholder owning 1.00% of the capital today would see that holding drop to 0.91% of capital on a non-diluted basis⁽³⁾, and to 0.84% of capital on a diluted basis⁽⁴⁾. Mauna Kea Technologies has the ability to stop this equity financing at any time.

Kepler Cheuvreux being a financial intermediary and a guarantor of the transaction, the shares will be issued based on the volume-weighted average price of the trading days preceding the issue, with a maximum discount of 6.5%.

At September 30, 2017, the Company had €7.0 million in available cash.

The number of share issued and listed under this facility shall be published in Euronext Paris market notices, and on the website of Mauna Kea Technologies.

The present issuance does not require the production of a prospectus subject to AMF approval.

(1) Leading to the issuance of a maximum of 2,100,000 new shares

(2) Based on the indicative volume-weighted average price of the last twenty trading days of Mauna Kea Technologies shares.

(3) Based on the 21,006,838 shares comprising the share capital of Mauna Kea Technologies as of September 30, 2017

(4) Under the assumption of the issuance of all 4,104,289 shares arising from the exercise of all existing dilutive instruments as of the date of the present press release (including this equity line).

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company's flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico. For more information on Mauna Kea Technologies, visit www.maunakeatech.com



Mauna Kea Technologies

Sacha Loiseau

CEO

investors@maunakeatech.com

United States

Zack Kubow / Lee Roth

The Ruth Group

646-536-7020 / 7012

zkubow@theruthgroup.com

lroth@theruthgroup.com

U.S. Media

Kirsten Thomas

The Ruth Group

508-280-6592

kthomas@theruthgroup.com

France and Europe

NewCap - Investor

Relations

Florent Alba

+33 (0)1 44 71 94 94

maunakea@newcap.fr

Kepler Chevreux

Thierry du Boislouveau

+33 6 01 06 60 20

Thierry.du-boislouveau@keplercf.com